Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

VSV-EBOVAC

Financiado

Cerrado

Vaccine safety and immunogenicity signatures of human responses to VSV ZEBOV S...

Vaccine safety and immunogenicity signatures of human responses to VSV ZEBOV Sofia ref. 115842 The proposal, VSV-EBOVAC, directly addresses the topic 1 of the IMI2 call on Ebola by supporting the clinical development of a highly promising new Ebola vaccine candidate, the vesicular stomatitis virus (VSV)‐ vectored Zaire Ebol... ver más

28/02/2019

TLS-S

5M€

Presupuesto del proyecto: 5M€

Líder del proyecto

Toscana Life Sciences Sviluppo No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 14 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-02-28

IMI2-2014-02-01: Vaccine development Phase I, II, an...

I+D

Cerrada hace 10 años

0% 81% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

14 Participantes

TLS-S

841.25K€ | Lider

BIOPROTECTION SYSTEMS CORPOR...

WBF

125.00K€ | Participante

UOXF

131.82K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

VSV-EBOPLUS SYSTEMS ANALYSIS OF ADULT AND PEDIATRIC RESPONSES TO THE VSV... 15M€ Cerrado

EBOVAC2 Development of a Prophylactic Ebola Vaccine Using an Heterol... 51M€ Cerrado

EBOVAC1 Development of a Prophylactic Ebola Vaccine Using an Heterol... 98M€ Cerrado

EBOVAC3 Bringing a prophylactic Ebola vaccine to licensure 51M€ Cerrado

EBO-PEP The EBO-PEP project : EBOla Zaïre Post-Exposure Prophylaxis,... 3M€ Cerrado

RBDCOV RBD Dimer recombinant protein vaccine against SARSCoV2 10M€ Cerrado

Duración del proyecto: 47 meses Fecha Inicio: 2015-03-19
Fecha Fin: 2019-02-28

Líder del proyecto

Toscana Life Sciences Sviluppo No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 5M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The proposal, VSV-EBOVAC, directly addresses the topic 1 of the IMI2 call on Ebola by supporting the clinical development of a highly promising new Ebola vaccine candidate, the vesicular stomatitis virus (VSV)‐ vectored Zaire Ebola vaccine (VSV-ZEBOV). In non-human primates, a single dose of VSV-ZEBOV elicited a strong (100%) and long-lasting protective efficacy against Ebola Zaire infections. Developed by Public Health Canada and manufactured by NewLink Genetics, VSV-ZEBOV was thus selected by the World Health Organization (WHO) as one of the 2 most promising vaccine candidates. To accelerate its clinical development, the WHO has organized a consortium and supported the organization of parallel first-in-man Phase I/II clinical trials, both in Europe and Africa. The primary objectives of these trials, initiated mid-November 2014, are to study the safety and antibody-inducing capacity of various doses of VSV-ZEBOV in European and African populations. We propose to build upon this asset to acquire new and critical knowledge of the innate and adaptive immune responses elicited in humans by VSV-ZEBOV vaccination, with specific emphasis on trancriptomics and metabolomics signatures. To this aim, we have constructed a consortium including representatives from the vaccine manufacturer, scientists of the 3 main clinical sites (Switzerland, Gabon, Kenya) and world-leaders in immunology and partners of ADITEC, a large FP7- supported collaborative research programme aiming to accelerate the development of novel, powerful immunisation technologies for next-generation vaccines. We propose an ambitious program using cutting-edge technologies to perform an in depth characterization of the clinical samples harvested before/after VSV-ZEBOV immunization of 200 volunteers in Switzerland, Gabon and Kenya, and to extend the recently initiated clinical studies up to 12 months to identify the signatures and determinants of persistent immune responses.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores